Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Chronic use application may help ease FDA's reluctance to make available a much anticipated and broadly applicable anticoagulant for the acute application in the original NDA.